Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
The purpose of this trial is to investigate the safety and efficacy of acasunlimab (also known as GEN1046) as monotherapy and in combination with pembrolizumab in patients with non-small cell lung cancer who have progressed during or after treatment of previous standard of care
Epistemonikos ID: 02445b4cf5a0c67f3c5d6e09fe2bdc6e37829db1
First added on: May 09, 2024